Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells

Fig. 5

Guadecitabine/ICBs stimulate IFN-γ production and cytotoxic activity on T and NK cells. A functional assay on spleen cells from different groups of treatments. Upper row: IFN-γ expression on CD3+, CD4+, CD8+ T and NK cells. Lower row: co-expression of CD107a (marker of degranulation and cytotoxic activity) and IFN-γ on CD3+, CD4+, CD8+ T, and NK cells. B functional assay on tumor-draining lymph node cells from different groups of treatments. Percentages of CD3+ IFN-γ+, CD4+ IFN-γ+, CD8+ IFN-γ+ and NKp46+ IFN-γ+ NK cells. *p<0.05, **p<0.02, ***p<0.01

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us